Aminex Therapeutics, Inc. 

COMPANY BACKGROUND

Aminex Therapeutics, Inc. was founded Dr. Mark R. Burns, previously the Executive Director of Chemistry at MediQuest Therapeutics, Inc. By leveraging 12 years of research and development that resulted in a suite of intellectual property in the form of three issued U.S. patents, Aminex expects to shorten the timeframe for product development dramatically. The initial discovery, optimization and animal proof-of-concept stages have been accomplished. Results summarized in a recent publication demonstrated that PBT treatment resulted in the majority (88%) of large aggressive cancers to exhibit complete or nearly complete remissions.1 Furthermore, upon stopping treatment, the majority of treated tumors did not re-grow; demonstrating that PBT provides a unique mechanism of action for prevention of reoccurrences. The company has been awarded a prestigious RAID grant from the National Cancer Institute that will help defray the costs of pre-clinical development efforts (the value of this work is estimated to be $800,000). A commitment for performance of a Phase I clinical trial has been obtained from a medical oncologist at the Fred Hutchinson Cancer Research Center in Seattle. Furthermore, a strategic partnership with a company developing PBT for veterinarian applications has been formed. Overall, the Company is well positioned to advance its novel inventions for the benefit of cancer patients.

COMPANY LEADERSHIP

Mark R. Burns, Ph.D., CEO and Scientific Founder

Dr. Burns is the scientific founder of the company.  He has had twelve years experience in the small company environment of a biotechnology firm.  His get-it-done attitude enabled him to advance four projects from inception through to advanced preclinical status.  Through these twelve years at MediQuest Therapeutics, he has learned to hone his entrepreneurial and scientific skills and was promoted from Senior Scientist to Director then Executive Director of Chemistry.  His mastery of polyamine chemistry and biology is demonstrated by his obtaining 15 issued United States Patents during his tenure at MediQuest Therapeutics, Inc.  Furthermore, he has published 21 scientific papers in a variety of international journals.  Dr. Burns has made important contributions to the scientific fields of medicinal, combinatorial, enzyme inhibitor design, analytical and process chemistry.  He earned his Ph.D. at the University of Michigan under Prof. James K. Coward and continued on to Rice University for post-doctoral training in bioorganic  chemistry with Prof. Ronald J. Parry.